Phenotyping Services
In 2012, GemPharmatech joined the International Mouse Phenotyping Consortium (IMPC), and in 2013, we completed the creation of an international phenotyping platform that meets international standards.
The standard analysis process begins at 9.5 days of embryonic development for phenotypic screening of mice. It continues up to 16 weeks, encompassing twenty major tests of cardiovascular, five senses, energy metabolism, bone, neurobehavior, blood biochemistry, blood cells, histomorphology, and others. Based on the phenotype analysis platform and self-developed novel models (such as severe immunodeficient NCG mice and immune checkpoint humanized mice), we have developed a phenotype analysis service system that includes tumor, metabolism, and overall phenotype screening and pharmacological pathology.
-
Efficacy and Pathology Platform
To promote bioscience research and accelerate the biopharmaceutical R&D process, GemPharmatech is committed to histopathology assays in animal models for a variety of diseases, gene knockout and knock-in mouse models, and other animal studies.
-
Metabolism Platform
GemPharmatech provides animal disease models and genetically humanized models for metabolic diseases, including diabetes mellitus, abnormal lipid metabolism, obesity, and NASH. The company additionally provides a series of in vivo R&D services, with corresponding disease models selected in light of the mechanism of action of the investigational drug.
-
Oncology Platform
GemPharmatech has successfully developed multiple PDX models, which cover cancers such as gastrointestinal, liver, pancreatic, lung, and hematologic, for a wide variety of uses, including efficacy evaluations, clinical studies as treatment control, and pathogenesis studies.